HK Stock Market Move | REMEGEN(09995) rose more than 7% during trading hours, announcing clinical data for PD-1/VEGF dual-targeted therapy for non-small cell lung cancer.

REMEGEN (09995) rose more than 7% intraday, up 5.57% to HK$81.5 as of press time, with a turnover of HK$3.1 billion. On the news front, on December 10, 2025, the European Society for Medical Oncology Immuno-Oncology Meeting (ESMO-IO) opened in London, UK. At the meeting, data from a Phase I/II clinical study (RC148-C001) of REMEGEN's independently developed PD-1/VEGF bispecific antibody RC148 as a monotherapy and combination therapy in first-line or second-line treatment of non-small cell lung cancer was officially released in poster form. The combination of RC148 20 mg/kg Q3W with docetaxel showed significantly superior efficacy, with an ORR of 66.7% and a DCR of 95.2%; benefits were observed in all subgroups, with an ORR of 80% in PD-L1 positive (TPS1%) patients; the median follow-up time was approximately 7 months, with a mPFS of 8.3 months. It is reported that in August of this year, RC148 has received FDA approval to conduct Phase II clinical trials in the United States. Sinolink's previous research report pointed out that RC148 had been approved to conduct clinical studies of monotherapy and combination therapy for advanced solid tumors in China as early as 2023. Obtaining FDA's IND approval marks the drug's entry into the global clinical development stage. The global BD transactions for PD-1/VEGF are hot, with AKESO and 3SBIO leading the way in BD licensing for international markets. RC148's clinical progress is at the forefront, and the initiation of clinical trials in the United States reflects the company's strong confidence, indicating promising potential for international markets in the future.